Rocket Pharmaceuticals, based in Cranbury, New Jersey, develops gene therapies for rare pediatric diseases and employs 268 people. The company targets conditions like Fanconi Anemia and Leukocyte Adhesion Deficiency-I.
Kinnari Patel bought 21,099 shares of RCKT on 9 April at $4.70 per share, worth a total of $99K. They now own 26,774 RCKT shares, or a 372% holding increase.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
